Rivastigmine Improves Appetite by Increasing the Plasma Acyl/Des-Acyl Ghrelin Ratio and Cortisol in Alzheimer Disease

BACKGROUND: Weight loss accelerates cognitive decline and increases mortality in patients with dementia. While acetylcholinesterase (AChE) inhibitors are known to cause appetite loss, we sometimes encounter patients in whom switching from donepezil (AChE inhibitor) to rivastigmine (AChE and butyrylc...

Descripción completa

Detalles Bibliográficos
Autores principales: Furiya, Yoshiko, Tomiyama, Takami, Izumi, Tesseki, Ohba, Naoki, Ueno, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921190/
https://www.ncbi.nlm.nih.gov/pubmed/29706984
http://dx.doi.org/10.1159/000487358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921190/
https://www.ncbi.nlm.nih.gov/pubmed/29706984
http://dx.doi.org/10.1159/000487358

Ejemplares similares